Author: Abhay Panchal

The Healthy Technology Act of 2025 proposes allowing AI to prescribe medications if state-authorized and FDA-approved, but experts caution that AI prescribing is not yet feasible. While AI assists in decision-making, it lacks the clinical judgment required for independent prescribing. Concerns include data bias, accuracy issues, and regulatory gaps, with no AI currently matching physician expertise. Experts compare AI prescribing to self-driving cars—promising, but requiring rigorous testing before mass adoption. Until prospective clinical trials prove AI’s reliability, the debate over AI’s role in medication management remains open.

Read More

Despite guidelines recommending screening for esophageal adenocarcinoma (OAC) and its precursor, Barrett’s esophagus (BO), uptake remains low due to the invasive nature and cost of endoscopy. Emerging non-endoscopic, swallowable cell collection devices combined with biomarker analysis have shown promising accuracy and safety, leading to their inclusion in screening guidelines. Pragmatic trials indicate patient interest, with up to 60% favoring capsule sponge-based screening, suggesting that minimally invasive alternatives could significantly enhance early detection and intervention efforts.

Read More

As the 100th anniversary of Crohn’s disease approaches, the field of inflammatory bowel disease (IBD) has seen remarkable advancements, including biologics, small molecules, and personalized treatment strategies. These innovations have improved patient outcomes and quality of life, yet challenges persist, such as the increasing global incidence, financial burdens, and therapeutic limitations. This special issue of Clinical Gastroenterology and Hepatology brings together experts to review recent breakthroughs and explore future directions in IBD care, emphasizing the need for ongoing research and novel therapeutic approaches.

Read More

Guardant Health has filed a lawsuit against rival Natera in California federal court, alleging that former employees stole thousands of confidential files to aid Natera’s development of competing cancer-detection blood tests. The lawsuit follows a previous $292.5 million false advertising verdict against Natera in November. Guardant claims its Shield test was the first FDA-approved early cancer blood test and accuses Natera of aggressively recruiting its employees to gain a competitive edge. Guardant seeks an injunction and monetary damages, while Natera denies the allegations, calling them baseless.

Read More

A randomized controlled trial comparing a digitally delivered gut-directed hypnotherapy (GDH) program (Nerva) to an active control found that GDH significantly improved IBS symptoms and quality of life. Among 240 participants, 81% of those using the GDH program experienced a ≥50-point decrease in IBS symptom severity compared to 63% in the control group (P = 0.002). GDH also led to a greater reduction in pain (71% vs. 35%, P < 0.001) and quality-of-life improvements (P < 0.001). These findings support digital GDH as an effective and accessible alternative to in-person behavioral interventions for IBS management.

Read More

In the rapidly evolving landscape of healthcare, few voices resonate as profoundly as that of Praveen Suthrum, renowned healthcare futurist, author, and co-founder of NextServices and GI Mastermind. Suthrum will give the opening keynote address at the upcoming AGA Tech Summit, providing context for what is happening now in the field and the transformative potential of innovation and technology in the years to come. AGA staff met with Suthrum to discuss his keynote address and his thoughts about the role of innovation in healthcare, and specifically in gastroenterology.A visionary perspectiveSuthrum’s insights are rooted in a deep understanding of the exponential growth of…

Read More

Vijay Yajnik, VP, Head of Gastroenterology TA, US Medical Affairs, highlights the clinical progress in eosinophilic esophagitis (EoE), emphasizing the impact of updated ACG clinical guidelines and the role of collaborative research in transforming underdiagnosed conditions. The evolution of EoE from a case-reportable rarity to a widely recognized disease demonstrates how consensus recommendations and structured guidelines enhance diagnosis, treatment, and awareness.

Read More